Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (April 2024)
8 slides from Radiopharm Theranostics's shareholder meeting presentation, Apr 15, 2024
Slide 1: Company Presentation – EGM April 2024
For personal use only Company Presentation – EGM April 2024 RADIOPHARM THERANOSTICS LTD 2024 1
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN
Slide 3: RAD is at the cutting edge of radiopharmaceuticals, a transformative modality within cancer
RAD IS AT THE CUTTING EDGE OF RADIOPHARMACEUTICALS, A TRANSFORMATIVE MODALITY WITHIN CANCER Differentiated Within Radiopharmaceuticals • Clinical-stage company with deep pipeline of radiotherapy assets pursuing novel targets within radiotherapy, leveraging insights For personal use only from ADCs, u
Slide 4: Company Pipeline
COMPANY PIPELINE TARGET & PROGRAM INDICATION Dx/Tx ISOTOPE PRECLINICAL PHASE I PHASE II NOTES MOLECULE PDL-1 NON-SMALL CELL RAD204 Therapy Lu177 *** Phase 1** enrolling in Australia For personal use only LUNG CANCER (Nanobody) FDA Orphan Drug Designation RAD301 Imaging Ga68 Integrin *** Phase 1* enr
Slide 5: BETABART: First and only B7-H3 radiopharmaceutical in development
BETABART®: First and only B7-H3 radiopharmaceutical in development BETABART® For personal use only Isoform-Selective Targeting of 4Ig-B7-H3 for PET Imaging and Beta-Radioligand Therapy LINKER CANCER CELL TARGET TARGETING RADIOACTIVE B7H3 MOLECULE ISOTOPE 177Lu Betabart B7-H3 (CD276) IS AN EXQUISITE
Slide 6: BETABART: 56% Increased Survival with single dose injection
BETABART®: 56% Increased Survival with single dose injection CT26 hB7H3 100uCi90Y-DOTA-MIL33B I.V. (n = 15) For personal use only 100 CT26 Vector 100uCi 90Y-DOTA-MIL33B I.V. (n = 9) 90 CT26 hB7H3 Saline I.V. (n = 23) 80 CT26 hB7H3 nothing (n = 20) 70 Percent Survival (* p = 0.0376, log-rank test) 60
Slide 7: Clinical Development & Regulatory Strategy
CLINICAL DEVELOPMENT & REGULATORY STRATEGY • Preclinical models validated selective targeting of tumor cells • Significant tumor reduction and increased survival in animal model For personal use only • GMP CMC production ongoing. GMP batch in Q3 2024 • GLP TOX and Biodistribution studies in Q3 –Q4 2
Slide 8: For personal use only
For personal use only RADIOPHARM THERANOSTICS LTD 2024 8
Radiopharm Theranostics — Shareholder Meeting (April 2024) on 6ix